Trials / Conditions / Sarcomatoid Renal Cell Carcinoma

Sarcomatoid Renal Cell Carcinoma

14 registered clinical trials studyying Sarcomatoid Renal Cell Carcinoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Su NCT07037004	City of Hope Medical Center	Phase 2
Recruiting	An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent NCT06447103	Jonsson Comprehensive Cancer Center	Phase 2
Active Not Recruiting	A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma NCT05808608	Hao Zeng	Phase 1 / Phase 2
Active Not Recruiting	Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell C NCT06049576	City of Hope Medical Center	Phase 1
Terminated	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid NCT04272034	Incyte Corporation	Phase 1
Active Not Recruiting	Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients NCT03793166	National Cancer Institute (NCI)	Phase 3
Recruiting	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted NCT03866382	National Cancer Institute (NCI)	Phase 2
Completed	ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) NCT03685448	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	Phase 2
Active Not Recruiting	Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcino NCT03541902	M.D. Anderson Cancer Center	Phase 2
Unknown	Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Meta NCT03177239	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	Phase 2
Active Not Recruiting	Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy NCT03055013	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourin NCT02496208	National Cancer Institute (NCI)	Phase 1
Completed	Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer NCT01767636	Mayo Clinic	Phase 2
Completed	Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer NCT00126503	National Cancer Institute (NCI)	Phase 1 / Phase 2